Suppr超能文献

前沿人类基因治疗:第一部分。基因递送技术。

State-of-the-art human gene therapy: part I. Gene delivery technologies.

作者信息

Wang Dan, Gao Guangping

机构信息

Gene Therapy Center, University of Massachusetts School of Medicine, 368 Plantation St., AS6-2011, Worcester, MA 01605, USA.

出版信息

Discov Med. 2014 Jul-Aug;18(97):67-77.

Abstract

Safe and effective gene delivery is a prerequisite for successful gene therapy. In the early age of human gene therapy, setbacks due to problematic gene delivery vehicles plagued the exciting therapeutic outcome. However, gene delivery technologies rapidly evolved ever since. With the advancement of gene delivery techniques, gene therapy clinical trials surged during the past decade. As the first gene therapy product (Glybera) has obtained regulatory approval and reached clinic, human gene therapy finally realized the promise that genes can be medicines. The diverse gene delivery techniques available today have laid the foundation for gene therapy applications in treating a wide range of human diseases. Some of the most urgent unmet medical needs, such as cancer and pandemic infectious diseases, have been tackled by gene therapy strategies with promising results. Furthermore, combining gene transfer with other breakthroughs in biomedical research and novel biotechnologies opened new avenues for gene therapy. Such innovative therapeutic strategies are unthinkable until now, and are expected to be revolutionary. In part I of this review, we introduced recent development of non-viral and viral gene delivery technology platforms. As cell-based gene therapy blossomed, we also summarized the diverse types of cells and vectors employed in ex vivo gene transfer. Finally, challenges in current gene delivery technologies for human use were discussed.

摘要

安全有效的基因传递是成功进行基因治疗的前提条件。在人类基因治疗的早期,由于有问题的基因传递载体而遭遇的挫折困扰着令人振奋的治疗成果。然而,从那时起基因传递技术迅速发展。随着基因传递技术的进步,在过去十年中基因治疗临床试验激增。随着首款基因治疗产品(Glybera)获得监管批准并进入临床,人类基因治疗终于实现了基因可以成为药物的承诺。如今可用的多种基因传递技术为基因治疗应用于治疗广泛的人类疾病奠定了基础。一些最迫切未满足的医疗需求,如癌症和大流行传染病,已经通过基因治疗策略得到解决,并取得了有希望的结果。此外,将基因转移与生物医学研究中的其他突破以及新型生物技术相结合,为基因治疗开辟了新途径。这种创新的治疗策略直到现在都是不可想象的,并且有望具有革命性。在本综述的第一部分,我们介绍了非病毒和病毒基因传递技术平台的最新进展。随着基于细胞的基因治疗蓬勃发展,我们还总结了在体外基因转移中使用的不同类型的细胞和载体。最后,讨论了当前用于人类的基因传递技术面临的挑战。

相似文献

2
The future of human gene therapy.
Mol Aspects Med. 2001 Jun;22(3):113-42. doi: 10.1016/s0098-2997(01)00004-8.
3
Viral vectors for gene transfer: a review of their use in the treatment of human diseases.
Drugs. 2000 Aug;60(2):249-71. doi: 10.2165/00003495-200060020-00002.
4
Progresses towards safe and efficient gene therapy vectors.
Oncotarget. 2015 Oct 13;6(31):30675-703. doi: 10.18632/oncotarget.5169.
5
Engineered Non-Viral Gene Vectors for Combination Cancer Therapy: A Review.
J Biomed Nanotechnol. 2017 Dec 1;13(12):1565-1580. doi: 10.1166/jbn.2017.2489.
6
Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective.
J Mol Med (Berl). 2022 Jun;100(6):875-901. doi: 10.1007/s00109-022-02208-0. Epub 2022 May 24.
8
Layer-by-Layer technique as a versatile tool for gene delivery applications.
Expert Opin Drug Deliv. 2021 Aug;18(8):1047-1066. doi: 10.1080/17425247.2021.1879790. Epub 2021 Feb 18.
9
Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery.
J Neuroimmune Pharmacol. 2017 Mar;12(1):51-83. doi: 10.1007/s11481-016-9724-3. Epub 2017 Feb 3.
10
Vectors and strategies for nonviral cancer gene therapy.
Expert Opin Biol Ther. 2016;16(4):443-61. doi: 10.1517/14712598.2016.1134480. Epub 2016 Jan 13.

引用本文的文献

1
Engineering and Bio/Nanotechnological Applications of Virus Particles.
Subcell Biochem. 2024;105:823-878. doi: 10.1007/978-3-031-65187-8_22.
2
Cancer vaccines: an update on recent achievements and prospects for cancer therapy.
Clin Exp Med. 2024 Dec 25;25(1):24. doi: 10.1007/s10238-024-01541-7.
4
Evaluation of a rapid multi-attribute combinatorial high-throughput UV-Vis/DLS/SLS analytical platform for rAAV quantification and characterization.
Mol Ther Methods Clin Dev. 2024 Jul 15;32(3):101298. doi: 10.1016/j.omtm.2024.101298. eCollection 2024 Sep 12.
5
Gene therapy: principles, challenges and use in clinical practice.
Wien Klin Wochenschr. 2025 May;137(9-10):261-271. doi: 10.1007/s00508-024-02368-8. Epub 2024 May 7.
6
Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases.
Pharmaceutics. 2024 Apr 13;16(4):535. doi: 10.3390/pharmaceutics16040535.
7
Adeno-associated virus as a delivery vector for gene therapy of human diseases.
Signal Transduct Target Ther. 2024 Apr 3;9(1):78. doi: 10.1038/s41392-024-01780-w.
8
Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.
Curr Gene Ther. 2024;24(5):356-376. doi: 10.2174/0115665232268840231222035423.
9
Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges.
Audiol Res. 2023 Dec 4;13(6):952-966. doi: 10.3390/audiolres13060083.
10
Gene Therapy for Regenerative Medicine.
Pharmaceutics. 2023 Mar 6;15(3):856. doi: 10.3390/pharmaceutics15030856.

本文引用的文献

1
Introducing Genes into Mammalian Cells: Viral Vectors.
Cold Spring Harb Protoc. 2020 Aug 3;2020(8):095513. doi: 10.1101/pdb.top095513.
2
Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles.
Mol Ther. 2008 Jul;16(7):1252-1260. doi: 10.1038/mt.2008.100. Epub 2016 Dec 8.
5
Engineering HSV-1 vectors for gene therapy.
Methods Mol Biol. 2014;1144:63-79. doi: 10.1007/978-1-4939-0428-0_5.
6
Current progress in gene delivery technology based on chemical methods and nano-carriers.
Theranostics. 2014 Jan 15;4(3):240-55. doi: 10.7150/thno.6914. eCollection 2014.
7
Herpes simplex virus-based nerve targeting gene therapy in pain management.
J Pain Res. 2014 Jan 20;7:71-9. doi: 10.2147/JPR.S36619. eCollection 2014.
8
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.
Nature. 2014 Feb 20;506(7488):382-6. doi: 10.1038/nature12875. Epub 2013 Dec 25.
9
The potential of adeno-associated viral vectors for gene delivery to muscle tissue.
Expert Opin Drug Deliv. 2014 Mar;11(3):345-364. doi: 10.1517/17425247.2014.871258. Epub 2014 Jan 3.
10
Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?
Clin Immunol. 2014 Jan;150(1):51-63. doi: 10.1016/j.clim.2013.11.004. Epub 2013 Nov 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验